News | August 08, 2025
Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
It is intended for contrast enhancement in MRI scans
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Subscribe To Our Newsletter & Stay Updated
